ebs molecular markers june-pptx - copy
TRANSCRIPT
![Page 1: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/1.jpg)
1
Evidence-Based Surgery
Role of Molecular Markers In Glioblastoma
Sanmugarajah Paramasvaran
John Fuller
14th June 2012
![Page 2: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/2.jpg)
2
Clinical Case
• 61 yr gentleman
• February 2012 – headache, left hemianopia
• MRI as shown
• Craniotomy for removal of tumour
• HPE : Glioblastoma
• WBRT and temozolamide
![Page 3: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/3.jpg)
3
Post Op Scan Recurrence in 10 weeks
![Page 4: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/4.jpg)
4
Clinical Questions:
Does molecular markers in glioblastoma have dependable diagnostic, prognostic and treatment guidance value to be considered as
routine investigation?
![Page 5: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/5.jpg)
5
Search strategy
• P = Patients with glioblastoma
• I = molecular markers
• C =
• O = better prognostic and treatment advice
Search Keywords (exp MESH )
1) “Molecular Markers” “
2) “Glioblastoma”
![Page 6: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/6.jpg)
6
DatabaseMedline OvidScopusCochrane
Search Keywords (exp MESH )
1) “Molecular Markers” “
2) “Glioblastoma”
![Page 7: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/7.jpg)
7
Search Process
![Page 8: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/8.jpg)
8
![Page 9: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/9.jpg)
9
Genetic Markers Tumour Markers
![Page 10: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/10.jpg)
10
![Page 11: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/11.jpg)
11
![Page 12: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/12.jpg)
12
Medline Ovid Search Results
![Page 13: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/13.jpg)
13
![Page 14: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/14.jpg)
14
Scopus
![Page 15: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/15.jpg)
15
Cochrane
Nil
![Page 16: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/16.jpg)
16
Selection Criteria
• Glioblatoma
• Molecular markers
• Diagnostic , prognostic and therapeutic significance
Exclusions: non GBM pathogenesis
![Page 17: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/17.jpg)
17
30 papers from Medline Ovid
![Page 18: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/18.jpg)
18
8 Papers from Scopus
![Page 19: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/19.jpg)
19
Levels of Evidence (NHMRC)
Class lll – 21 papers
7 prospective cohorts
14 retrospective cohorts
Class lV- 17 papers
![Page 20: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/20.jpg)
20
Conclusion
Marina N. Nikiforova, MD; Ronald L. Hamilton, MD, Arch Pathol Lab Med. 2011;135:558–568
MOLECULAR MARKERS SIGNIFICANCE
MGMT PROGNOSTICPREDICTIVE
EGFR AMPLIFICATION DIAGNOSTIC
IDH1 DIAGNOSTIC IN SECONDARY GBM(60-90%)
IDH 1 & 2 BETTER PROGNOSIS
PTEN DIAGNOSTIC OF PRIMARY GBM
![Page 21: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/21.jpg)
21
• Hegi and colleague reported , with temozolamide and RT
MGMT Alive at 2 yrs
Unmethylated 15%
Methylated 49%
![Page 22: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/22.jpg)
22
![Page 23: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/23.jpg)
23
IDH1 & 2 mutation - survival( 31 vs 15 months)
![Page 24: Ebs molecular markers june-pptx - copy](https://reader036.vdocument.in/reader036/viewer/2022062418/55498a86b4c90554648b52f5/html5/thumbnails/24.jpg)
24
Thank You